{"schema_version":"secwatch.filing_event.v1","accession":"0001077183-22-000169","form_type":"8-K","ticker":"NEO","cik":"0001077183","company_name":"NEOGENOMICS INC","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.531355+00:00","generated_at":"2026-06-22T02:47:45.761114+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NeoGenomics Q3 revenue $129M (+6%); net loss widens to $37M, adjusted EBITDA -$12M","bullets":["Revenue $129M (+6% YoY); Clinical Services $106M (+4%), Pharma Services $23M (+18%).","Test volume -1% YoY; revenue per test +5% to $392.","Net loss $37M (vs $20M loss in Q3 2021); prior year included $18M gain on Inivata investment.","Adjusted EBITDA -$12M (vs -$3M); Adjusted Net Loss -$18M (vs -$10M).","Cash and marketable securities $444M at quarter end."],"urls":{"canonical":"https://secwatch.observer/filing/0001077183-22-000169","json":"https://secwatch.observer/filing/0001077183-22-000169.json","markdown":"https://secwatch.observer/filing/0001077183-22-000169.md","text":"https://secwatch.observer/filing/0001077183-22-000169.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000169/0001077183-22-000169-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000169/neo-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T02:47:45.761114+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"981fd74031d2bf6aade45d7260b9ad24fc09e930","claim":"NEOGENOMICS INC reported the third quarter of 2022 results: revenue $129 million, net income $37 million.","evidence_excerpt":"Third-Quarter Results Consolidated revenue for the third quarter of 2022 was $129 million, an increase of 6% over the same period in 2021. Clinical Services revenue of $106 million was an increase year-over-year of 4%. Clinical test volume (1) decreased by 1% year-over-year. Average revenue per clinical test (“revenue per test”) increased by 5% to $392. Pharma Services revenue increased by 18% to $23 million compared to the third quarter of 2021. Consolidated gross profit for the third quarter of 2022 was $48.9 million, an increase of 4% compared to the third quarter of 2021. This increase was primarily due to an increase in revenue partially offset by higher payroll and payroll-related costs. Consolidated gross profit margin, including amortization of acquired Inivata developed technology intangible assets, was 38.0%. Adjusted Gross Profit Margin (2) , excluding amortization of acquired Inivata developed technology intangible assets, was 41.7%. Operating expenses for the third quarter","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000169/0001077183-22-000169-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2022"},{"label":"Revenue","value":"$129 million"},{"label":"Net income","value":"$37 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}